Abstract
Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Silverman LB, Weinstein HJ . Treatment of childhood leukemia Curr Opin Oncol 1997 9: 26–33
Ghetie V, Vitetta ES . Immunotoxins in the therapy of cancer: from bench to clinic Pharm Ther 1994 63: 209–234
Pastan I, Brinkmann U . Immunotoxins against cancer Biochim Biophys Acta 1994 1198: 27–45
Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES . Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study Blood 1995 85: 3457–3465
Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES . A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy Blood 1993 82: 2624–2633
Selvaggi K, Saria EA, Schwartz R, Vlock DR, Ackerman S, Wedel N, Kirkwood JM, Jones H, Ernstoff MS . Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-MeI) immunoconjugate plus cyclosporine A in patients with metastatic melanoma J Immunother 1993 13: 201–207
Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P . Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins Leuk Lymphoma 1994 13: 441–448
LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V . Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma Blood 1991 78: 1173–1182
Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli MF, Stirpe F . Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin Lancet 1992 339: 1195–1196
Conry RM, Khazaeli MB, Saleh MN, Ghetie V, Vitetta ES, Liu T, Lobuglio AF . Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration J Immunother 1995 18: 231–241
Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES . A phase I study of bolus vs continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma Blood 1996 88: 1188–1197
Current Clinical Trials, Oncology. (Book on CD-ROM) Green Brook: New Jersey 1999
Ghetie M, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, Amlot P, Vitetta ES, Thorpe PE . Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy Cancer Res 1988 48: 2610–2617
May RD, Vitetta ES, Moldenhauer G, Dorken B . Selective killing of normal and neoplastic human B cells with anti-CD19 and anti-CD22 ricin a chain immunotoxins Cancer Drug Del 1986 3: 261–270
Shen G, Li J, Ghetie M, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, Janossy G, Amlot P, Vitetta ES, Thorpe PE . Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B cell leukemias and lymphomas Int J Cancer 1988 42: 792–797
Ghetie M, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES . Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites Cancer Res 1991 51: 5876–5880
Ghetie M, Tucker K, Richardson J, Uhr JW, Vitetta ES . The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin Blood 1992 80: 2315–2320
Ghetie M, Podar EM, Gordon BE, Pantazis P, Vitetta ES . Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma Int J Cancer 1996 68: 93–96
Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Uhr JW, Thorpe PE . Phase I immunotoxin trial in patients with B cell lymphoma Cancer Res 1991 51: 4052–4058
Hurwitz R, Hozier J, LeBien T, Minowada J, Gaji-Peczalska K, Kubonishi I, Kersey J . Characterization of a leukemic cell line of the pre-B phenotype Int J Cancer 1979 23: 174–180
Campana D, Coustan-Smith E, Kumagai M, Manabe A . Growth requirements of normal and leukemic human B cell progenitors Leuk Lymphoma 1994 13: 359–371
Kincade PW, Lee G, Pietrangeli CE, Hayashi SI, Gimble JM . Cells and molecules that regulate B lymphopoiesis in bone marrow Ann Rev Immunol 1989 7: 111–143
Ghetie M, Tucker K, Richardson J, Uhr JW, Vitetta ES . Eradication of minimal disease in severe combined immunodeficient mice with disseminated daudi lymphoma using chemotherapy and an immunotoxin cocktail Blood 1994 84: 702–707
Nadler LM, Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds) . Leukocyte Typing II. B-cell/leukemia panel workshop: summary and comments Springer-Verlag: New York 1986 p 3
Sato S, Teddler TF, Kishimoto T, Kukutani H et al (eds). BC3, CD19 Workshop Panel report. Leukocyte Typing VI. White Cell Differentiation Antigens, 6th edn Garland Publishing: New York 1999 pp 133–134
Scheuermann RH, Racila E . CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy Leuk Lymphoma 1995 18: 385–397
Uckun FM, Gaji-Peczalska KJ, Kersey JH, Houston LL, Vallera DA . Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia J Exp Med 1986 163: 347–368
Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU . Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19-and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone Int J Cancer 1995 62: 337–344
Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D . Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia Blood 1992 79: 2370–2377
Jain RK . Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J Natl Cancer Inst 1989 81: 570–576
Acknowledgements
This work was supported by Pediatric Oncology Group Novel Scientific Initiative Grant and NIH Grant T-32-CA09640. We thank Angela Mobley and Carol Walsh for excellent assistance with the FACS analysis. We also thank Darla Tate for her acquisition and transfer of patient specimens to our laboratory and the faculty and fellows in the Center for Cancer and Blood Disorders at Children's Medical Center of Dallas.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herrera, L., Farah, R., Pellegrini, V. et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14, 853–858 (2000). https://doi.org/10.1038/sj.leu.2401779
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401779
Keywords
This article is cited by
-
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
Leukemia (2007)
-
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
Nature Clinical Practice Rheumatology (2006)
-
Engineered antibodies act as targeted therapies in cancer treatment
The Indian Journal of Pediatrics (2005)
-
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins
Leukemia (2003)
-
Requirement for SAPK–JNK signaling in the induction of apoptosis by ribosomal stress in REH lymphoid leukemia cells
Leukemia (2003)